This could explain why tirzepatide (which stimulates the GIP pathway in addition to GLP -1) can be administered at higher doses than semaglutide (which only stimulates GLP-1), without amplifying the side effects typical of GLP-1 agonists (nausea, vomiting)
Its actually backed by multiple double-blinded human randomized controlled trials using a peptide called: tesamorelin
Moreover, IF is contraindicated in patients with specific rare metabolic or genetic disorders, such as pyruvate carboxylase deficiency (PCD) (159), primary carnitine deficiency (PCD) (160), carnitine-acylcarnitine translocase (CACT) deficiency (161), 3-hydroxyacyl-CoA dehydrogenase deficiencies, including both medium-chain (MCHAD) and long-chain (LCHAD) forms (162, 163), medium-chain acyl-CoA dehydrogenase deficiency (MCADD) (164), very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD) (165), and porphyria (166)
2 Bioactive compounds in microalgae Microalgae constitute a promising and sustainable source of bioactive compounds with significant potential for applications in the food industry (Sun et al., 2023)
Even peptides for anti-aging may play a role in overall metabolic health optimization
